Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. The company`s lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop antiviral Fc-conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and Coronavirus. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Website: cidara.com



Growth: Bad revenue growth rate -87.5%, there is slowdown compared to average historical growth rates 59.3%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -94.9%. Gross margin is high, +81.1%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 43 096.1% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2.2x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $2.2 mln (-0.011% of cap.)

Key Financials (Download financials)

Ticker: CDTX
Share price, USD:  (0.0%)221.38
year average price 91.50  


year start price 23.47 2025-02-12

min close price 16.43 2025-04-04

max close price 221.38 2026-01-12

current price 221.38 2026-02-11
Common stocks: 90 504 622

Dividend Yield:  0.0%
EV / Sales: 509.6x
Margin (EBITDA LTM / Revenue): -94.9%
Fundamental value created in LTM:
Market Cap ($m): 20 036
Net Debt ($m): -160
EV (Enterprise Value): 19 876
Price to Book: 47.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-24defenseworld.net

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?

2026-01-02fool.com

Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?

2025-11-19forbes.com

Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025

2025-11-18marketbeat.com

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

2025-11-17reuters.com

Merck expects over $5 billion commercial opportunity from Cidara's flu drug

2025-11-14globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)

2025-11-14wsj.com

Merck to Buy Cidara Therapeutics in $9.2 Billion Deal

2025-11-14reuters.com

Merck bets on flu prevention with about $9.2 billion deal for Cidara Therapeutics

2025-11-14seekingalpha.com

Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring

2025-10-21seekingalpha.com

Cidara Therapeutics: A Potential Blockbuster In Flu Prevention
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-13 2024-05-15 2023-11-02 2023-08-03 2023-05-11 2022-11-03
acceptedDate 2025-11-06 16:25:59 2025-08-07 16:15:59 2025-03-06 16:25:45 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10 2022-03-07 17:12:46 2021-02-25 16:36:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 1M 0 302 000 8M 23M 13M 8M 26M 64M 41M 50M 12M
costOfRevenue 45M 0 0 0 57 000 2M 37M 387 000 401 000 0 0 0 73M 0
grossProfit -45M 0 1M 0 245 000 7M -13M 12M 7M 26M 64M 41M -24M 12M
grossProfitRatio 0 0 0 0.811 0.815 0.97 0.947 1 1
researchAndDevelopmentExpenses 36M 25M 157M 12M 7M 12M 37M 17M 17M 19M 77M 20M 73M 68M
generalAndAdministrativeExpenses 8M 7M 21M 0 5M 6M 14M 4M 3M 4M 21M 6M 19M 16M
sellingAndMarketingExpenses 0 0 0 0 -57 000 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 8M 7M 21M 5M 5M 6M 14M 4M 3M 4M 21M 6M 19M 16M
otherExpenses 0 -4M 0 0 85M 0 -37M 0 0 0 0 0 -73M 0
operatingExpenses 44M 27M 177M 17M 11M 18M 14M 21M 20M 23M 98M 26M 19M 84M
costAndExpenses 89M 27M 177M 17M 11M 19M 50M 21M 20M 23M 98M 26M 92M 84M
interestIncome 0 2M 6M 2M 0 365 000 2M 613 000 623 000 232 000 191 000 0 0 0
interestExpense 0 0 0 0 0 0 0 0 623 000 232 000 0 55 000 0 262 000
depreciationAndAmortization 28 000 27 000 233 000 61 000 57 000 56 000 112 000 22 000 -263 000 320 000 143 000 310 000 189 000 1M
ebitda -83M -27M -176M -17M -11M -11M -27M -9M -13M 3M -33M 15M -42M -71M
ebitdaratio 0 0 0 -36.57 -1.263 -0.673 -1.685 0.115 0.374
operatingIncome -89M -27M -176M -17M -11M -11M -27M -9M -13M 3M -34M 15M -42M -72M
operatingIncomeRatio 0 0 0 -36.758 -1.263 -0.673 -1.685 0.115 0.366
totalOtherIncomeExpensesNet 5M 2M 6M 2M 2M 365 000 2M 613 000 623 000 232 000 191 000 55 000 -212 000 -262 000
incomeBeforeTax -83M -26M -170M -16M -94M -10M -25M -8M -12M 3M -33M 15M -42M -72M
incomeBeforeTaxRatio 0 0 0 -311.954 -1.22 -0.624 -1.603 0.123 0.368
incomeTaxExpense 0 0 0 0 -5M -56 000 15 000 -230 000 149 000 213 000 272 000 -110 000 0 0
netIncome -83M -26M -170M -16M -89M -10M -23M -8M -12M 3M -34M 15M -42M -72M
netIncomeRatio 0 0 0 -296.06 -1.22 -0.643 -1.623 0.123 0.368
eps -3.1 -1.65 -26.75 -2.38 -19.59 -2.28 -5.25 -0.091 -0.14 0.03 -9.61 0.17 -16.2 -36.03
epsdiluted -3.1 -1.65 -2.38 -19.59 -2.28 -0.091 -0.14 0.03 0.17
weightedAverageShsOut 16M 16M 6M 7M 5M 5M 4M 90M 90M 79M 3M 70M 3M 2M
weightedAverageShsOutDil 16M 16M 6M 7M 5M 5M 4M 90M 90M 101M 3M 89M 3M 2M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-04-22 2023-03-23 2022-03-07 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 6M 2M 191 000 0 -262 000
ebit -176M -27M -34M -42M -72M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -170M -25M -34M -42M -72M
netIncomeFromDiscontinuedOperations 464 000 2M 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 1 0 0 0
bottomLineNetIncome -170M -25M -34M -42M -75M
epsDiluted -26.75 -5.25 -9.61 -16.19 -36.03

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-13 2024-05-15 2023-11-02 2023-08-03 2023-05-11 2022-11-03
acceptedDate 2025-11-06 16:25:59 2025-08-07 16:15:59 2025-03-06 16:25:45 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10 2022-03-07 17:12:46 2021-02-25 16:36:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 294M 511M 190M 127M 164M 29M 36M 49M 50M 48M 33M 53M 62M 36M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 294M 511M 190M 127M 164M 29M 36M 49M 50M 48M 33M 53M 62M 36M
netReceivables 2M 2M 2M 2M 2M 7M 16M 3M 5M 26M 6M 5M 5M 11M
inventory 0 0 0 0 0 7M 6M 2M 2M 0 0 0 -3M 0
otherCurrentAssets 147M 19M 19M 28M 2M 3M 3M 4M 4M 6M 0 6M 3M 7M
totalCurrentAssets 443M 532M 211M 157M 169M 47M 61M 58M 62M 79M 45M 64M 72M 57M
propertyPlantEquipmentNet 2M 2M 4M 4M 5M 5M 5M 5M 5M 1M 1M 2M 3M 1M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 50M 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 551 000 0
otherNonCurrentAssets 24M 95 000 96 000 1M 104 000 986 999 1M 1M 1M 1M 1M 1M 533 000 2M
totalNonCurrentAssets 76M 3M 4M 6M 5M 6M 6M 6M 6M 2M 2M 3M 4M 3M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 519M 534M 215M 162M 173M 53M 67M 63M 68M 82M 47M 67M 75M 60M
accountPayables 4M 2M 4M 3M 2M 5M 4M 4M 2M 4M 1M 4M 1M 5M
shortTermDebt 2M 1M 0 2M 3M 1M 0 1M 942 000 1M 0 1M 3M 7M
taxPayables 0 0 26M 26M 26M 21M 18M 0 0 0 12M 0 0 0
deferredRevenue 0 0 0 0 0 24M 25M 15M 15M 16M 15M 15M 14M 14M
otherCurrentLiabilities 90M 29M 44M 14M 8M 35M 32M 16M 14M 15M 5M 12M 10M 4M
totalCurrentLiabilities 96M 32M 50M 44M 40M 65M 67M 36M 31M 36M 41M 33M 34M 39M
longTermDebt 424 000 836 000 0 2M 3M 3M 0 3M 4M 0 0 344 000 0 0
deferredRevenueNonCurrent 0 0 0 0 0 2M 4M 17M 18M 19M 21M 24M 18M 11M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 -2M 0 -17M -18M 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 0 0 2M 0 17M 18M 0 0 4M 0 0
totalNonCurrentLiabilities 424 000 836 000 2M 2M 3M 5M 8M 20M 21M 19M 21M 25M 20M 11M
otherLiabilities 0 0 0 0 1 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 2M 4M 4M 4M 3M 5M 4M 5M 1M 1M 2M 2M 939 000
totalLiabilities 96M 33M 51M 47M 42M 70M 75M 55M 53M 55M 62M 58M 54M 50M
preferredStock 0 0 0 0 1 0 0 0 0 0 0 0 0 0
commonStock 3000 2000 1000 1000 1000 1000 9000 9000 9000 9000 7000 7000 7000 4000
retainedEarnings -744M -660M -611M -559M -543M -452M -441M -424M -416M -404M -419M -394M -377M -335M
accumulatedOtherComprehensiveIncomeLoss -107 000 0 0 0 0 0 0 0 -0 0 0 0 0 0
othertotalStockholdersEquity 1 166M 1 162M 675M 674M 434M 432M 432M 431M 403M
totalStockholdersEquity 422M 501M 163M 116M 131M -18M -8M 8M 15M 27M -14M 9M 22M 11M
totalEquity 422M 501M 163M 116M 131M -18M -8M 8M 15M 27M -14M 9M 22M 11M
totalLiabilitiesAndStockholdersEquity 519M 534M 162M 173M 53M 63M 68M 82M 67M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 519M 534M 215M 162M 173M 53M 67M 63M 68M 82M 47M 67M 75M 60M
totalInvestments 50M 0 0 0 0 0 0 0 0 0 0 0 0 0
totalDebt 2M 2M 4M 4M 4M 5M 5M 4M 5M 1M 1M 2M 5M 8M
netDebt -292M -508M -186M -123M -160M -24M -31M -44M -46M -47M -32M -51M -57M -28M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-04-22 2023-03-23 2022-03-07 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 2M 16M 6M 5M 11M
otherReceivables 0 0 0 0 0
prepaids 0 0 7M 4M 3M
totalPayables 4M 4M 13M 1M 5M
otherPayables 0 0 12M 0 0
accruedExpenses 0 5M 8M 5M 8M
capitalLeaseObligationsCurrent 2M 1M 1M 1M 939 000
capitalLeaseObligationsNonCurrent 2M 4M 0 1M 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 775M 433M 404M 399M 345M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX CDTX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-07 2024-08-13 2024-05-15 2023-11-02 2023-08-03 2023-05-11 2022-11-03
acceptedDate 2025-11-06 16:25:59 2025-08-07 16:15:59 2025-03-06 16:25:45 2024-11-07 16:08:31 2024-08-13 16:15:14 2024-05-15 16:09:06 2024-04-22 16:56:44 2023-11-02 16:05:17 2023-08-03 16:01:05 2023-05-11 16:12:08 2023-03-23 07:00:50 2022-11-03 17:27:10 2022-03-07 17:12:46 2021-02-25 16:36:32
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -83M -26M -170M -13M -94M -10M -23M -8M -12M 3M -34M 15M -42M -72M
depreciationAndAmortization 28 000 27 000 233 000 61 000 57 000 56 000 118 000 22 000 -263 000 320 000 143 000 310 000 -1M 229 000
deferredIncomeTax 0 6M 0 0 0 0 0 0 0 0 0 0 0 0
stockBasedCompensation 3M 3M 4M 751 000 703 000 795 000 3M 796 000 795 000 640 000 4M 843 000 4M 4M
changeInWorkingCapital 39M -15M -14M 13M -16M 3M -4M 5M 14M -16M 454 000 10M 14M 13M
accountsReceivables -2000 -165 000 14M 650 000 5M 9M -10M 3M 20M -20M -477 000 -210 000 6M -11M
inventory 0 0 6M 0 7M -1M -6M -513 000 -2M 0 0 0 1M -7M
accountsPayables 64M -13M -1M 3M -5M -5M 9M 4M -246 000 3M -2M 0 -1M 7M
otherWorkingCapital -24M -2M -33M 9M -23M -331 000 4M -468 000 -4M 1M 3M 10M 9M 25M
otherNonCashItems 160 000 -9M 3M -38M -1M -2M 1M 270 000 229 000 475 000 982 000 2M 15 000 21 000
netCashProvidedByOperatingActivities -41M -41M -177M -37M -104M -7M -22M -2M 3M -11M -28M 28M -25M -54M
investmentsInPropertyPlantAndEquipment 0 0 -129 000 -106 000 0 -23 000 -505 000 -126 000 -107 000 -94 000 -118 000 -9000 -41 000 -186 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites -176M 0 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -176M 0 -106 000 0 -23 000 -126 000 -107 000 -94 000 -9000
debtRepayment 0 0 -75 000 -75 000 -50 000 0 0 0 -371 000
commonStockIssued -1M 383M -107 000 239M -4000 9M -261 000 26M 1M
commonStockRepurchased 0 0 0 0 0 -39 000 0 63 000 161M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 1M 137 000 0 4000 -39 000 -9M -161M 14 000 -720 000
netCashUsedProvidedByFinancingActivities 160 000 383M -182 000 239M -93 000 9M -261 000 26M 107 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 6M 0 0 0 0 0 0
netChangeInCash -217M 342M 160M -37M 135M -7M 3M -2M 2M 15M -30M 28M 19M -17M
cashAtEndOfPeriod 300M 517M 196M 127M 164M 29M 36M 49M 50M 48M 33M 53M 62M 43M
cashAtBeginningOfPeriod 517M 174M 36M 164M 29M 36M 33M 50M 48M 33M 62M 25M 43M 60M
operatingCashFlow -41M -41M -177M -37M -104M -7M -22M -2M 3M -11M -28M 28M -25M -54M
capitalExpenditure 0 0 -129 000 -106 000 0 -23 000 -505 000 -126 000 -107 000 -94 000 -118 000 -9000 -41 000 -186 000
freeCashFlow -41M -41M -177M -37M -104M -7M -23M -2M 3M -11M -29M 28M -25M -55M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-03-06 2024-04-22 2023-03-23 2022-03-07 2021-02-25
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -129 000 -505 000 -118 000 -41 000 -186 000
netDebtIssuance -276 000 0 -3M -4M -3M
longTermNetDebtIssuance -276 000 0 -3M -4M -3M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 337M 26M 2M 49M 40M
netCommonStockIssuance 337M 26M 2M 49M 40M
commonStockIssuance 337M 26M 2M 49M 40M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 7000 21 000 -720 000 6000 14 000
netCashProvidedByFinancingActivities 337M 26M -951 000 45M 37M
incomeTaxesPaid 95 000 797 000 0 0 0
interestPaid 0 0 40 000 0 0

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-08 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-14 08:16 ET
Cidara Therapeutics published news for 2025 q3
SEC form 8
2025-11-14 08:16 ET
Cidara Therapeutics published news for 2025 q3
SEC form 8
2025-11-14 08:16 ET
Cidara Therapeutics published news for 2025 q3
SEC form 8
2025-11-14 08:16 ET
Cidara Therapeutics published news for 2025 q3
SEC form 10
2025-11-06 16:25 ET
Cidara Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:11 ET
Cidara Therapeutics published news for 2025 q3
SEC form 8
2025-11-06 16:11 ET
Cidara Therapeutics published news for 2025 q3
SEC form 10
2025-08-07 20:15 ET
Cidara Therapeutics published news for 2025 q2
SEC form 8
2025-08-07 20:09 ET
Cidara Therapeutics published news for 2025 q2
SEC form 8
2025-08-07 20:09 ET
Cidara Therapeutics published news for 2025 q2
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-25 20:39 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-23 11:05 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-06-23 11:05 ET
Cidara Therapeutics published news for 2025 q1
SEC form 10
2025-05-08 20:47 ET
Cidara Therapeutics reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Cidara Therapeutics reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cidara Therapeutics published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Cidara Therapeutics published news for 2025 q1
SEC form 10
2025-03-06 21:25 ET
Cidara Therapeutics reported for 2024 q4
SEC form 10
2025-03-06 00:00 ET
Cidara Therapeutics reported for 2024 q4
SEC form 8
2025-03-06 00:00 ET
Cidara Therapeutics published news for 2024 q4
SEC form 8
2025-03-06 00:00 ET
Cidara Therapeutics published news for 2024 q4
SEC form 8
2024-11-07 16:13 ET
Cidara Therapeutics published news for 2024 q3
SEC form 8
2024-11-07 16:13 ET
Cidara Therapeutics published news for 2024 q3
SEC form 10
2024-11-07 16:08 ET
Cidara Therapeutics published news for 2024 q3
SEC form 10
2024-08-13 16:15 ET
Cidara Therapeutics published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Cidara Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Cidara Therapeutics published news for 2024 q2
SEC form 8
2024-08-13 00:00 ET
Cidara Therapeutics reported for 2024 q2
SEC form 8
2024-05-15 16:22 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-05-15 16:22 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-05-15 16:09 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Cidara Therapeutics reported for 2024 q1
SEC form 10
2024-04-22 16:56 ET
Cidara Therapeutics published news for 2023 q4
SEC form 10
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2023 q4
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 8
2024-04-22 00:00 ET
Cidara Therapeutics published news for 2024 q1
SEC form 10
2023-11-02 16:05 ET
Cidara Therapeutics reported for 2023 q3
SEC form 10
2023-11-02 00:00 ET
Cidara Therapeutics reported for 2023 q3
SEC form 8
2023-11-02 00:00 ET
Cidara Therapeutics reported for 2023 q3
SEC form 6
2023-08-03 16:03 ET
Cidara Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 16:01 ET
Cidara Therapeutics reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Cidara Therapeutics reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Cidara Therapeutics reported for 2023 q2
SEC form 6
2023-06-23 16:07 ET
Cidara Therapeutics published news for 2023 q1
SEC form 6
2023-05-11 16:16 ET
Cidara Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 16:12 ET
Cidara Therapeutics reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Cidara Therapeutics reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Cidara Therapeutics reported for 2023 q1
SEC form 6
2023-04-27 16:40 ET
Cidara Therapeutics published news for 2023 q1
SEC form 6
2023-03-29 17:26 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-23 07:05 ET
Cidara Therapeutics reported for 2022 q4
SEC form 10
2023-03-23 07:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 10
2023-03-23 00:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 8
2023-03-23 00:00 ET
Cidara Therapeutics reported for 2022 q4
SEC form 6
2023-03-13 21:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:20 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-13 21:19 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-06 16:23 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-02 16:21 ET
Cidara Therapeutics published news for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-03-01 07:22 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-02-14 08:05 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2023-01-27 16:33 ET
Cidara Therapeutics published news for 2022 q4
SEC form 6
2022-12-16 16:06 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-11-10 16:06 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-11-03 17:30 ET
Cidara Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 17:27 ET
Cidara Therapeutics reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Cidara Therapeutics reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Cidara Therapeutics reported for 2022 q3
SEC form 6
2022-10-31 17:28 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-10-21 17:02 ET
Cidara Therapeutics published news for 2022 q3
SEC form 6
2022-09-19 20:28 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-13 18:51 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-13 18:40 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-08 16:55 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-09-02 17:14 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-08-09 17:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 17:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Cidara Therapeutics reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Cidara Therapeutics reported for 2022 q2
SEC form 6
2022-07-27 08:00 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-07-07 16:07 ET
Cidara Therapeutics published news for 2022 q2
SEC form 6
2022-06-24 16:12 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-05-11 16:08 ET
Cidara Therapeutics published news for 2022 q1
SEC form 10
2022-05-11 16:06 ET
Cidara Therapeutics published news for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Cidara Therapeutics reported for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Cidara Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 16:33 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-04-04 16:06 ET
Cidara Therapeutics published news for 2022 q1
SEC form 6
2022-03-07 17:15 ET
Cidara Therapeutics published news for 2021 q4
SEC form 10
2022-03-07 17:12 ET
Cidara Therapeutics published news for 2021 q4
SEC form 10
2022-03-07 00:00 ET
Cidara Therapeutics published news for 2021 q4
SEC form 8
2022-03-07 00:00 ET
Cidara Therapeutics published news for 2021 q4
SEC form 6
2022-03-04 16:29 ET
Cidara Therapeutics published news for 2021 q4
SEC form 6
2021-12-14 07:05 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-11-10 16:30 ET
Cidara Therapeutics published news for 2021 q3
SEC form 10
2021-11-10 16:29 ET
Cidara Therapeutics published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Cidara Therapeutics published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-10-08 17:19 ET
Cidara Therapeutics published news for 2021 q3
SEC form 6
2021-09-21 16:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-09-01 08:10 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-08-17 08:31 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-08-12 16:31 ET
Cidara Therapeutics published news for 2021 q2
SEC form 10
2021-08-12 16:27 ET
Cidara Therapeutics published news for 2021 q2
SEC form 10
2021-08-12 00:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 8
2021-08-12 00:00 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-07-20 16:30 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-07-01 16:11 ET
Cidara Therapeutics published news for 2021 q2
SEC form 6
2021-06-23 19:04 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-05-17 16:06 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-05-13 16:15 ET
Cidara Therapeutics published news for 2021 q1
SEC form 10
2021-05-13 16:12 ET
Cidara Therapeutics published news for 2021 q1
SEC form 8
2021-05-13 00:00 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-28 16:07 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 18:45 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-04-05 07:07 ET
Cidara Therapeutics published news for 2021 q1
SEC form 6
2021-02-25 16:40 ET
Cidara Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 16:36 ET
Cidara Therapeutics published news for 2020 q4
SEC form 6
2021-01-25 08:00 ET
Cidara Therapeutics published news for 2020 q4
SEC form 6
2020-12-07 17:13 ET
Cidara Therapeutics published news for 2020 q3
SEC form 6
2020-11-30 16:17 ET
Cidara Therapeutics published news for 2020 q3
SEC form 6
2020-11-05 16:13 ET
Cidara Therapeutics published news for 2020 q3
SEC form 10
2020-11-05 16:09 ET
Cidara Therapeutics published news for 2020 q3